Showing results (91-100 of 119) with videos related to
Sort By:
Pageof 12
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 3, 2009
Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosisPierre D Delmas, Francoise Munoz, Dennis M Black, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 31, 2008
Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United StatesSarah J Glover, Martin Gall, Oliver Schoenborn-Kellenberger, et al.The Journal of Clinical Endocrinology and Metabolism|July 2, 2009
Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral densityRichard Eastell, Dennis M Black, Steven Boonen, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 3, 2004
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosisCharles H Chesnut, Arne Skag, Claus Christiansen, et al.Current Medical Research and Opinion|September 14, 2006
Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trialRobert Recker, Paul Lips, Dieter Felsenberg, et al.Clinical Therapeutics|May 19, 2009
Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) studyRonald Emkey, Pierre D Delmas, Michael Bolognese, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 13, 2007
Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled studyPaul D Miller, Arkadi A Chines, Claus Christiansen, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 25, 2009
Early impairment of trabecular microarchitecture assessed with HR-pQCT in patients with stage II-IV chronic kidney diseaseJustine Bacchetta, Stéphanie Boutroy, Nicolas Vilayphiou, et al.Calcified Tissue International|November 15, 2012
A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year dataMichael R McClung, Claude-Laurent Benhamou, Zulema Man, et al.Joint Bone Spine|October 12, 2004
Estimated number of women likely to benefit from bone mineral density measurement in FranceNassira Amamra, Claudine Berr, Françoise Clavel-Chapelon, et al.Pageof 12